Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy

Reuters

Jan 08

<a href="https://laohu8.com/S/COYA">Coya Therapeutics</a> Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy

Coya Therapeutics Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia (FTD). Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell (Treg) numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment (MOCA) scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108513635) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601316364"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601316364\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601316364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601316364","market":"nz","top_or_hot":-1,"title":"Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia (FTD). Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell (Treg) numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment (MOCA) scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108513635) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia (FTD). Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell (Treg) numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment (MOCA) scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108513635) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COYA","symbol_name":"COYA THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL71ZfjW:1","article_id":"2601316364","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601316364","pubTimestamp":1767877292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Coya Therapeutics Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia . Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell  numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment  scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COYA":"COYA THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Coya Therapeutics报告低剂量IL-2和CTLA4-Ig联合疗法FTD研究阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COYA":0.9},"content_text":"Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy\n    \n\n        Coya Therapeutics Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia (FTD). Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell (Treg) numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment (MOCA) scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108513635) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}